CervoMed, BOSTON, July 9, 2026
CervoMed Inc. has announced the successful completion of enrollment in its Phase 2a clinical trial evaluating neflamapimod for the treatment of nonfluent variant primary progressive aphasia (nfvPPA), one of the most common forms of frontotemporal dementia (FTD) associated with tau pathology. The company also confirmed that interim biomarker data from the study has been accepted for presentation at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, scheduled for November 16–19, 2026, in Boston. The enrollment milestone represents a significant step forward for the investigational therapy as nfvPPA currently has no approved treatments in either the United States or the European Union. CervoMed noted that recently published peer-reviewed findings in Nature Neuroscience further strengthen the scientific rationale for targeting p38α kinase, supporting neflamapimod’s potential as a disease-modifying therapy for tau-driven neurodegenerative disorders.
Phase 2 Trial Evaluates Safety, Pharmacokinetics, and Clinical Activity
The Phase 2a study enrolled 25 participants diagnosed with nfvPPA, who received oral neflamapimod at either 40 mg three times daily (TID) or 80 mg twice daily (BID) over a 24-week treatment period, followed by a 12-week randomized, double-blind, placebo-controlled extension. Conducted across leading academic medical centers in the United States, the trial is designed to evaluate the drug’s safety, pharmacokinetics, and clinical effects in patients with this progressive neurodegenerative disease. According to Chief Executive Officer Dr. John A. Alam, rapid enrollment reflects both the strong support from the academic FTD community and the urgent need for effective therapies. The company expects to report the first interim biomarker data in early fourth quarter 2026, while the initial clinical efficacy data are anticipated during the first quarter of 2027, providing important insights into the therapy’s potential clinical benefit.
Nature Neuroscience Findings Strengthen Scientific Rationale for p38α Inhibition
Supporting the ongoing clinical program, a recently published study in Nature Neuroscience demonstrated that abnormal tau accumulation disrupts axonal transport during the early stages of frontotemporal dementia, contributing to neuronal dysfunction and disease progression. Using transgenic mouse models carrying disease-associated MAPT mutations, researchers showed that inhibition of p38α kinase significantly improved axonal transport and reversed key pathological deficits. The study further demonstrated that neflamapimod, a selective p38α inhibitor, successfully reproduced these therapeutic effects, reinforcing its biological mechanism of action in tau-related FTD. Since approximately half of all FTD cases are driven by tau pathology, these findings provide additional evidence supporting the clinical development of neflamapimod as a potential disease-modifying therapy capable of improving neuronal health by targeting fundamental disease mechanisms rather than simply managing symptoms.
Advertisement
Neflamapimod Targets Significant Unmet Need in Rare Neurodegenerative Disease
Nonfluent variant primary progressive aphasia is a rare form of frontotemporal dementia characterized by the gradual loss of speech production while language comprehension initially remains relatively preserved. As the disease progresses, patients experience increasing difficulty speaking, understanding complex language, planning daily activities, and maintaining motor function. It is estimated that 10,000–15,000 people in the United States and 15,000–20,000 individuals across the European Union are living with nfvPPA, yet no approved therapies currently exist. Neflamapimod, an orally administered small-molecule therapy capable of crossing the blood-brain barrier, selectively inhibits p38 MAP kinase alpha, a key driver of neuroinflammation, synaptic dysfunction, and neurodegeneration. The investigational therapy received U.S. FDA Orphan Drug Designation for FTD in 2024 and continues to advance across multiple neurological indications, including Dementia with Lewy Bodies (DLB), ischemic stroke recovery, and amyotrophic lateral sclerosis (ALS). Completion of enrollment in the Phase 2 nfvPPA study marks another important milestone in CervoMed’s strategy to develop targeted therapies addressing significant unmet needs across neurodegenerative diseases.
Source: CervoMed press release
